RARB and prostate cancer: The sensitivity of the MS-MLPA technique was evaluated by constructing a curve based on the generation of different proportions (5, 10, 20, 40, 80, 100 %) of DNA derived from a prostate cancer cell line (LNCaP) with known methylation of GSTP1, RASSF1, SCGB3A1, CASP8, RARB, CD44, APC, RUNX3, CCND2, spiked in genomic DNA (control) from a blood sample of a healthy donor.